Drug Profile

Gadoquatrane - Bayer

Alternative Names: BAY-1747846

Latest Information Update: 05 Dec 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Bayer
Class Contrast media; Gadolinium-containing contrast agents; Heavy metals; Macrocyclic compounds
Mechanism of Action Magnetic resonance imaging enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preregistration CNS disorders
Phase III Peripheral nervous system diseases

Most Recent Events

03 Dec 2025 Preregistration for CNS disorders (Diagnosis, In adolescents, In children, In infants, In neonates) in China (IV)
03 Dec 2025 Efficacy, adverse events and pharmacokinetics data from a phase III trial in CNS disorders released by Bayer
27 Aug 2025 US FDA accepts NDA for Gadoquatrane for CNS disorders for review

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com